Pictet Asset Management (UK)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Pictet Asset Management (UK)’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$2.12M	Buy	106,323 +4,147	+4%	+$82.2K	﹤0.01%	1000
2021 Q1	$2.36M	Sell	102,176 -17,500	-15%	-$488K	﹤0.01%	959
2020 Q4	$2.96M	Sell	119,676 -3,600	-3%	-$119K	﹤0.01%	923
2020 Q3	$5.11M	Buy	123,276 +23,459	+24%	+$1.08M	0.01%	716
2020 Q2	$4.78M	Sell	99,817 -849	-0.8%	-$65.6K	0.01%	699
2020 Q1	$6.34M	Buy	100,666 +15,300	+18%	+$1.37M	0.01%	578
2019 Q4	$10.6M	Buy	85,366 +44,345	+108%	+$3.97M	0.02%	568
2019 Q3	$2.72M	Buy	41,021 +4,500	+12%	+$302K	0.01%	819
2019 Q2	$2.91M	Sell	36,521 -66,879	-65%	-$5.99M	0.01%	807
2019 Q1	$11.6M	Buy	103,400 +34,300	+50%	+$3.75M	0.03%	507
2018 Q4	$6.96K	Buy	69,100 +19,400	+39%	+$2.01M	0.02%	579
2018 Q3	$6.28M	Sell	49,700 -6,100	-11%	-$646K	0.01%	676
2018 Q2	$4.68M	Buy	55,800 +4,200	+8%	+$308K	0.01%	679
2018 Q1	$3.17M	Buy	+51,600	New	+$3.11M	0.01%	742
2017 Q4	–	Sell	-9,909	Closed	-$575K	–	914
2017 Q3	$575K	Sell	9,909 -8,100	-45%	-$872K	﹤0.01%	848
2017 Q2	$2.02M	Sell	18,009 -88,654	-83%	-$10.3M	0.01%	786
2017 Q1	$12.1M	Buy	106,663 +10,031	+10%	+$1.17M	0.04%	445
2016 Q4	$10.5M	Buy	96,632 +7,721	+9%	+$920K	0.04%	439
2016 Q3	$14.6M	Sell	88,911 -47,026	-35%	-$7.41M	0.06%	372
2016 Q2	$20.2M	Buy	135,937 +110,487	+434%	+$16.1M	0.08%	290
2016 Q1	$2.83M	Sell	25,450 -27,444	-52%	-$3.24M	0.01%	642
2015 Q4	$7.9M	Buy	52,894 +4,193	+9%	+$710K	0.03%	457
2015 Q3	$8.08M	Buy	48,701 +4,678	+11%	+$1.03M	0.04%	442
2015 Q2	$11.6M	Buy	44,023 +17,624	+67%	+$4.69M	0.05%	396
2015 Q1	$6.67M	Sell	26,399 -9,555	-27%	-$2.07M	0.03%	523
2014 Q4	$5.61M	Buy	35,954 +30,254	+531%	+$5.59M	0.03%	546
2014 Q3	$1.35M	Buy	5,700 +700	+14%	+$178K	0.01%	774
2014 Q2	$1.18M	Buy	5,000 +200	+4%	+$52.7K	0.01%	775
2014 Q1	$1.58M	Buy	+4,800	New	+$1.62M	0.01%	757

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Pictet Asset Management (UK)'s ICPT Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 4.1% in Q2 2021, buying an estimated $82.2K and bringing the position to 106,323 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1000.

Pictet Asset Management (UK) first reported a position in ICPT in Q1 2014 and has held it in 29 quarters since. The position peaked at $20.2M in Q2 2016. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

Pictet Asset Management (UK) held 106,323 shares of Intercept Pharmaceuticals, Inc. worth $2.12M as of Q2 2021.
Pictet Asset Management (UK) bought 4,147 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $82.2K.
Intercept Pharmaceuticals, Inc. made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #1000 holding.
Pictet Asset Management (UK) first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and has held it in 29 quarters since.
Pictet Asset Management (UK)'s Intercept Pharmaceuticals, Inc. position peaked at $20.2M in Q2 2016.
129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.